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During the last few years substantial evidence has been raised for the involvement of inflammatory processes in the 
pathophysiology of Chronic Obstructive Pulmonary Diseases (COPD) and asthma. Concerning pulmonary diseases we 
are particularly interested in the modulatory function of the alveolar macrophage (AM). This cell plays a predominant 
role by exhibiting its typical inflammation-related properties as phagocytosis, cytotoxicity, antigen-presentation and 
the production of pro- and antiinflammatory mediators, proteolytic enzymes and oxygen-radicals. Many of these 
functions are known to be inhibited by increasing hatracellular levels of cyclic AMP (c-AMP), a second messenger 
formed through the activation of adenyl cyclase. In our research, we examine the modulation of the adenyl cyclase 
system in alveolar macrophages with a special interest to the role of this cell in COPD and asthma. In a previous tudy 
in our laboratory, using an animal model for human allergic asthma, we observed an increase in the sensitivity of the 
adenyl cyclase system in antigen chal!enged AMs, probably the result of changes which have occured in this system on 
the level of the regulatory bindh~g protehls (1). In the presented study we examined the effects of some inflammatory 
mediators and fl-adrenergic drugs on the adenyl cyclase activity of normal human alveolar macrophages. AMs were 
obtained by broncho alveolar lavage (BAL) of 29 healthy smolcing (n ffi 25) and non-smoking (n = 4), male (n - 4) and 
female (n = 25) subjects; mean age was 34:1:9.4 years. All subjects did not receive any medication during three weeks 
prior to BAL and had no history of pulmonary disorders. We did not exclude smoking subjects from this study as 
similar results were found between smokers and non-smokers in basal c-AMP levels (smokers: 2.47:1:0.08 vs. 
non-smokers: 2.94 + 0.45 pmol c-AmP/1 • 10  6 cells) and c-AMP response clue to agonist-exposure; the viability of the 
cells recovered from BAL was 90.9 + 0.88% whereas the majority (> 95 ~) consisted of AMs as differentiated by 
May-Griinwald-Giemsa taining. The inflammatory mediators prostaglandin E2 (PGE2), prostacyclin (DC-PGI2, a 
stable analogue) and histanfine induced a close-dependent i crease of basal c-AMP levels in AMs (PGE2: 379-61%, 
DC-PGI2:231 _+ 51 ~, histamine: 115:1: 35?o; dose-range from 2~8- 10 -s - 2.8- 10 -4 M) whereas platelet activating 
factor (PAF) had no effect on AM adenyl cyclase (dose-range from 1-10 -12-  1.10 -5 M). Using the selective 
histaminergic receptor antagonists Mepyramine and Cimeticline (1 • 10-5 M), it was shown that the effect of histamine 
was mediated via H2-receptors. The non-selective and full ~-adrenergic ago.nist isoprena!ine iaduced an increase of 
basal c-AMP levels of 175 _4- 36 ~ whereas the/32-selective adrenerl!;ic agonist salbutamol induced an increase of only 
76 _ 10 %. Again, using fl-adrenoceptor antagonists, it was :~;hown that the effects of isoprenaline and salbutamol n 
AM adenyl cyclase were mediated through fl2-receptors. These results show that the inflammatory mediators PGE 2, 
DC-PGI 2 and histamine and fl-adrenergic drugs can stimulate adenyl cyclase of human AMs whereas PAF has no 
effect. Furthermore it was shown that smoking seems to have no effects on the AM-adenyl cyclase activity and that 
human AMs possess functional H2-histaminergic and fl2-adrenergic receptors coupled to adenyl cyclase. Apparently, 
mediators and frequently used anti-asthmatic dr~,,gs (like salbutamol and anti-histaminics) have besides their action on 
bronchial smooth muscles an important decreasing effect on macrophage-activity. Future studies include the effects of 
inflammatory mediators and drugs used in the tre, atment of bronchi~d hyperreactivity on the modulation of the adenyl 
cyclase system in AMs of patients with COPD and asthma with a special reference to the relationship between the 
adenyl cyclase system, the guanyl cyclase system and arachidonic acid metabolism. 
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The med ia tors  involved in airway hyperresponsiveness and airway inflammation in ra t  
a l lerg ic  as thma 
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Bronchial hyperresponsiveness is a very important determinant for bronchial asthma. Recently, the relationship 
between airway hyperresponsiveness and inflammation has been attracted attention. In the present study, the changes 
in airway responsiveness of acetylcholine (ACh)-induced bronchoconstriction a d in airway vascular permeability, 
after DNP-Ascaris (DNP-Asc) antigen challenge, were investigated by using a rat allergic asthma. The relationship 
among airway hyperreactivity, immediate asthmatic response (IAR) and airway inflammation was thus referred. Male 
Wistar rats were actively sensitized with DNP-Asc together with killed Bordetella pertussis vaccine as an adjuvant, 
according to the method of Tada and Okumura (1971). Five days later, the animals were boosted with DNP-Asc. At 
the eighth day after the first /mmunization, they were challenged by inhalation of the antigen. The experiment 
investigating airway hyperresponsiveness wa performed as the following. At first, an asthmatic reaction was induced 
by aerosolized DNP-Asc (6 mgP/ml) challenge for 10 min in a chamber under non-anesthesia. After 24 hr, rats were 
anesthetized with pentobarbital (50 mg/kg, i.p.) and immobilized with pancuronium (1 mg/kg, i.v.) under artificial 
respiration. ACh solutions (0.003~-0.3~,) were inhaled, in the increasing order, at intervals of 2 min with an ultrasonic 
nebul/zer. Airway constriction was measured with a modified Konzett-RSssler method and expressed as a change in 
ventilation overflow (VO). In the second experiment on IAR, the response was induced by DNP-Asc challenge under 
anesthesia, nd the airway constriction immediately evoked was measured as a change in VO. The third experiment on 
investigating airway vascular permeability was performed as the following. Rats were challenged with DNP-Asc under 
non-anesthesia. Following 1, 6 or 24 hr, they were anesthetized and i.v. administered Evans blue (E.B.; 30 mg/kg) and 
heparin (600 U/kg). After bleeding and thoracotomy, the amount of E.B. extracted from airway tissues was measured 
by the method of Evans et al. (1987). To investigate the chemical mediators involved in the airway hyperresponsive- 
ness, IAR and airway vascular permeability, the following drugs were administered before DNP-Asc challenge: 
chlorpheniramine (H1 blocker), indomethacin (cyclooxygenase inhibitor), ONO-1078 (5-1ipoxygenase inhibitor), CV- 
3988 (PAF antagonist), OKY-046 (thromboxane A 2 synthetase inhibitor), and a combination of CV-3988 and 
OKY-046. At 24 hr after DNP-Asc challenge, the airway responsiveness to ACh was significantly increased. The 
increase was inhibited by pretreatments with ONO-1078, CV-3988 and OKY-046. Prominent IAR induced after 
DNP-Asc challenge in all the animals was inhibited by pretreatments with chlorpheniramine, indomethacin, CV-3988 
and ONO-1078. Furthermore, airway vascular permeability was significantly increased at 24 hr after DNP-Asc 
challenge. The increase was inhibited by pretreatments with ONO-1078, CV-3988 and OKY-046. From the above 
res~t~s, it~ ;~ suggested that the chemical mediators involved in might !~e as follows: leukotrienes, PAF ~,~d 
thromboxane A 2 in the airway hyperresponsiveness; hi tamine, prostaglandins, PAF and leukotrienes in IAR, and 
leukotrienes, PAF and thromboxane A 2 in airway inflammation. A close relationship between the airway hyperre- 
sponsiveness and airway inflammation is suggested. 
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